PDCD1 and glioblastoma: Although immunotherapies targeting programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have shown efficiency in certain tumors [9], their consistent failures in the case of GBM are attributed to its classification as an “immunologically cold” tumor.